In bid to improve patient adherence, the U.S. National Institutes of Health is funding and helping run two clinical trials of long-acting injectable HIV candidates being developed by Johnson & Johnson's Janssen and GlaxoSmithKline.
The National Center for Complementary and Integrative Health at the National Institutes of Health (NIH) has proposed conducting large research studies of nondrug pain management approaches. It did so in a report by a working group of the Center's Advisory Council.
In-transition drug developer AMRI has won a 10-year contract with the National Institutes of Health to help develop and manufacture neurological drugs.
The National Institutes of Health is launching The Neuro Startup Challenge, a crowdsourcing competition featuring 72 teams from 80 hospitals and universities, with a goal of commercializing 16 of its neuroscience inventions, including enhancements to MRI machines.
The race for an Ebola vaccine is ramping up with positive Phase I data from an experimental vaccine made by GlaxoSmithKline and the NIH's National Institute of Allergy and Infectious Diseases. And thanks to those results, larger trials could be on the way soon.
The Department of Health and Human Services and the National Institutes of Health are proposing new rules that would greatly expand the number of clinical trials required to publicize their results, a move that could change how CROs handle data.
If the U.S. National Institutes of Health gets its way, any researcher it funds will have to publish a summary of their clinical trial results and adverse events, regardless of whether the trial succeeded or failed.
Federal regulators are proposing a rule that would require makers of drugs and medical devices to publicize the results of thousands of clinical trials, regardless of whether they succeed, part of a global move toward transparency in R&D.
The DNA Medicine Institute, developer of a diagnostic device that can perform hundreds of clinical lab tests with a single drop of blood, won the Nokia Sensing Xchallenge for promising medical sensing technologies.
Geisinger Health System has added another component to the genomic variant database it is helping to create as part of a $25 million National Institutes of Health initiative. The new addition gives patients the option to submit their genetic test results and other health information to a registry.